The E542K substitution is a somatic mutation in p110alpha that has been associated with tumours of the colon and brain. Combined in vitro and in vivo studies have shown that this mutation confers higher lipid kinase activity than wild type, and is able to induce oncogenic transformation.
Application: Complex of N-terminal 6His-tagged, recombinant, full-length human p110alpha containing the mutation E542K & untagged, recombinant, full-length human p85alpha. For use in Kinase Assays.
Legal Information: UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes: For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.